Anti-Mouse NKG2A/C/E Antibody (20D5)
Based on 1 Customer Validation
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonal antibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8+ T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma.
For research use only. We do not sell to patients.
- Purity: 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Rat IgG2a kappa
Mouse
NKG2A/C/E
Anti-Mouse NKG2A/C/E Antibody (20D5) (10 μg/mL, 4 h) enhances the perforin dependent cytotoxicity of liver mononuclear cells (MNCs), but has no effect on FasL/Fas dependent cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse NKG2A/C/E Antibody (20D5) (200 μg, i.v., once every 3-4 days, for 3 times) significantly inhibits tumor growth conbinated with PD-L1 mAb in female C57BL/6J or BALB/c mice bearing A20 or RMA-Rae-1β tumors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Con A (10 mg/kg, i.v.) induced C57BL/6 mice or α-GalCer induced (2 μg, i.p.) DBA/2J mice[1]
-
Dosage:300 μg
-
Administration:Intraperitoneal injection (i.p.), single dose, 2 days before Con A or α-GalCer injection
-
Result:Increased serum AST and ALT levels.
Aggravated liver pathological damage.
Increased serum IFNγ levels.
-
Animal Model:5×106 RMA-Rae-1β cells injected female C57BL/6J or 5×106 A20 cells injected BALB/c mice[2]
-
Dosage:200 μg, conbinated with PD-L1 mAb (50 μg for BALB/c mice and 200 μg for C57BL/6J mice)
-
Administration:Intravenous injection (i.v.), once every 3-4 days for 3 times
-
Result:Significantly inhibited tumor growth (75% BALB/c mice survive), relying on NK and CD8+ T cells.
Significantly inhibited tumor growth (45% C57BL/6J mouse survival) and induced long-lasting anti-tumor memory CD8+ T cells.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo NKG2A blockade (see description); in vitro NKG2A blockade; Immunohistochemistry (frozen);
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse NKG2A/C/E Antibody (20D5)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kawamura T, et al. NKG2A inhibits invariant NKT cell activation in hepatic injury. J Immunol. 2009 Jan 1;182(1):250-8. [Content Brief]
[2]. André P, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018 Dec 13;175(7):1731-1743.e13. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse NKG2A/C/E Antibody (20D5) Related Classifications
HY-P990180 Related Classifications
Powered by Bioz